Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation

[Display omitted] Heat Shock Protein 90 (Hsp90) has been extensively explored as a potential drug target for cancer therapies. 17- N-allylamino- 17-demethoxygeldanamycin (17AAG) was the first Hsp90 inhibitor to enter clinical trials for cancer therapy. However, native drug is being shown to have con...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of pharmaceutics Vol. 511; no. 1; pp. 648 - 658
Main Authors:	Rochani, Ankit K., Balasubramanian, Sivakumar, Ravindran Girija, Aswathy, Raveendran, Sreejith, Borah, Ankita, Nagaoka, Yutaka, Nakajima, Yoshikata, Maekawa, Toru, Kumar, D. Sakthi
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 10-09-2016
Subjects:	17AAG Animals Cancer chemotherapy Cell Line, Tumor Cell Survival - drug effects Cell Survival - physiology Drug Compounding - methods Ferric Compounds - administration & dosage Ferric Compounds - metabolism HSP90 Heat-Shock Proteins - antagonists & inhibitors HSP90 Heat-Shock Proteins - chemistry HSP90 Heat-Shock Proteins - metabolism Hsp90 inhibitor Humans Mice Nano formulation Nanoparticles - administration & dosage Nanoparticles - metabolism Nanotechnology Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Polymers - administration & dosage Polymers - metabolism Protein Structure, Secondary Cancer chemotherapy Hsp90 inhibitor 17AAG Nano formulation Nanotechnology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!